GRAIL, Inc.
About GRAIL, Inc.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $147.2M
- Net income
- -$408.4M
- Total assets
- $2.9B
- Market cap
- $2.6B
- Operating margin
- -382.0%
- Net margin
- -277.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $147.2M
- Operating expenses
- $709.3M
- Operating income
- -$562.2M
- Income tax
- -$126.2M
- Net income
- -$408.4M
- EPS (basic)
- $-11.11
- EPS (diluted)
- $-11.11
Balance sheet
- Total assets
- $2.9B
- Current assets
- $953.8M
- Total liabilities
- $344.2M
- Current liabilities
- $79.7M
- Shareholders’ equity
- $2.6B
Cash flow
- Operating cash flow
- -$299.0M
- Investing cash flow
- -$85.0M
- Financing cash flow
- $423.3M
- Net cash flow
- $39.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.6B
- EPS (diluted)
- $-11.11
- Shares outstanding
- 41.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 12, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $408.4M in FY2025.
- Revenue grew 17% from FY2024 to FY2025.
- Trading 47% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GRAIL, Inc..
Write a review
News about GRAIL, Inc.
News & sentiment via Polygon.io
